Nonalcoholic fatty liver disease and bariatric surgery

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 2, 2012, Pages 163-171

  Stephen, Sindu ^a   Baranova, Ancha ^b,c   Younossi, Zobair M ^a,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

bariatric surgery; inflammation; NAFLD; NASH; outcomes; steatosis; weight loss

Indexed keywords

BIOLOGICAL MARKER; LORCASERIN; PHENTERMINE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE;

BARIATRIC SURGERY; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE COURSE; EXERCISE; GASTRIC BANDING; HISTOPATHOLOGY; HUMAN; LIFESTYLE MODIFICATION; LIPID STORAGE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER HISTOLOGY; LONGITUDINAL STUDY; MOLECULAR PATHOLOGY; NONALCOHOLIC FATTY LIVER; NUTRITIONAL COUNSELING; OBESITY; OUTCOME ASSESSMENT; PHYSIOLOGICAL PROCESS; REVIEW; SLEEVE GASTRECTOMY;

BARIATRIC SURGERY; BIOLOGICAL MARKERS; BIOPSY; FATTY LIVER; HUMANS; OBESITY; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84858034571     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.97     Document Type: Review

References (75)

1. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132, 112-117 (2000). (Pubitemid 30044177)
2. Lam B, Younossi ZM. Novel treatment strategies for patients witn nonalcoholic fatty liver disease. Clin. Invest. 1(2), 229-239 (2011).
3. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37(4), 917-923 (2003). (Pubitemid 36397405)
4. Weiner RA. Surgical treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Dig. Dis. 28(1), 274-279 (2010).
5. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: A practical approach to evaluation and management. Clin. Liver Dis. 13(2), 249-266 (2009).
6. Sanyal AJ. NASH: A global health problem. Hepatol. Res. 41(7), 670-674 (2011).
7. Blackburn GL, Hutter MM, Harvey AM et al. Expert panel on weight loss surgery: Executive report update. Obesity (Silver Spring) 17(5), 842-862 (2009).
8. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol. Res. 33(2), 68-71 (2005). (Pubitemid 41799777)
9. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313-1321 (2005). (Pubitemid 40770284)
10. Brunt EM, Kleiner DE, Wilson LA et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 53(3), 810-280 (2011).
11. Arun J, Jhala N, Lazenby AJ, Clements R, Abrams GA. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes. Surg. 17(2), 155-161 (2007). (Pubitemid 47091575)
12. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128(7), 1898-1906 (2005). (Pubitemid 40824701)
13. Merriman RB, Ferrell LD, Patti MG et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44(4), 874-880 (2006). (Pubitemid 46489551)
14. Ratziu V, Bugianesi E, Dixon J et al. Histological progression of non-alcoholic fatty liver disease: A critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther. 26(6), 821-830 (2007). (Pubitemid 47346702)
15. Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 34(6 Pt 2), 643-648 (2008).
16. Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 189-200 (2011).
17. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5(2), 233-244 (2011).
18. Tarantino G, Conca P, Riccio A et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: Is it really benign? J. Transl. Med. 6, 72 (2008).
19. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. Digestion 83(1-2), 124-133 (2011).
20. Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev. Mol. Diagn. 7(2), 195-205 (2007). (Pubitemid 46513445)
21. Tataranni PA, Ortega E. A burning question: Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on Type 2 diabetes? Diabetes 54(4), 917-927 (2005). (Pubitemid 40446304)
22. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 132(6), 2169-2180 (2007). (Pubitemid 46693756)
23. Verrijken A, Francque S, Mertens I et al. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int. J. Obes. (Lond.) 34(5), 899-907 (2010).
24. Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg. 16(9), 1118-1125 (2006). (Pubitemid 44433145)
25. Estep M, Armistead D, Hossain N et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 32(3), 487-497 (2010).
26. Baranova A, Schlauch K, Elariny H et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes. Surg. 17(8), 1111-1118 (2007). (Pubitemid 350042936)
27. Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168(15), 1609-1616 (2008).
28. Tarantino G, Colicchio P, Conca P et al. Young adult obese subjects with and without insulin resistance: What is the role of chronic inflammation and how to weigh it non-invasively? J. Inflamm. (Lond.) 6, 6 (2009).
29. Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am. J. Gastroenterol. 100, 1072-1081 (2005). (Pubitemid 40769044)
30. Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B et al. Clinical trial: A nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 30(10), 999-1009 (2009).
31. Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 27(1), 103-107 (1997). (Pubitemid 27357062)
32. Solga S, Alkhuraishe AR, Clark JM et al. Dietary composition and nonalcoholic fatty liver disease. Dig. Dis. Sci. 49, 1578-1583 (2004). (Pubitemid 39335538)
33. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335(7631), 1194-1199 (2007). (Pubitemid 350273303)
34. Mallat A, Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig. Dis. 28(1), 261-266 (2010).
35. Coletta DK, Bates SH, Jones RB, Bailey CJ. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: Preliminary data. Diab. Vasc. Dis. Res. 3(3), 186-188 (2006). (Pubitemid 44902485)
36. Aberle J, Freier A, Busch P et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes. Surg. 19(11), 1504-1507 (2009).
37. Florakis D, Diamanti-Kandarakis E, Katsikis I et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: A randomized, 24-week study. Int. J. Obes. (Lond.) 32(4), 692-699 (2008). (Pubitemid 351536017)
38. Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 56(3), 443-444 (2007). (Pubitemid 46579783)
39. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 49(1), 80-86 (2009).
40. Wilson NS, Shah N, Manitpisitkul W et al. Liver failure requiring transplantation after orlistat use. Pharmacotherapy 31(11), 1145 (2011).
41. No authors listed. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann. Intern. Med. 115(12), 956-961 (1991).
42. Glatt D, Sorenson T. Metabolic and bariatric surgery for obesity: A review. South Dakota Med. 57-62 (2011).
43. Mechanick JI, Kushner RF, Sugerman HJ et al. American Association of Clinical Endocriologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and non-surgical support of the bariatric surgery patient. Surg. Obes. Relat. Dis. 4, S109-S184 (2008).
44. Ribeireiro T, Swain J, Sarr M et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery - a prospective analysis. Obes. Surg. 21(3), 310-315 (2011).
45. Zhao Y, Enciosa W. CT Bariatric Surgery Utilization and Outcomes in 1998 and 2004. Statistical Brief #23. Agency for Healthcare Research and Quality, MD, USA (2007).
46. Padwal R, Klarenbach S, Wiebe N et al. Bariatric surgery: A systematic review of the clinical and economic evidence. J. Gen. Intern. Med. 26(10), 1183-1194 (2011).
47. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann. Surg. 205, 613-624 (1987). (Pubitemid 17103382)
48. Belachew M, Legrand M, Vincenti VV et al. Laparoscopic placement of adjustable silicone gastric band in the treatment of morbid obesity: How to do it. Obes. Surg. 5, 66-70 (1995).
49. Himpens J, Dapri G, Cadiére GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: Results after 1 and 3 years. Obes. Surg. 16, 1450-1456 (2006). (Pubitemid 44759977)
50. Halverson JD, Wise L, Wazna MF, Ballinger WF. Jejunoileal bypass for morbid obesity. A critical appraisal. Am. J. Med. 64, 461-475 (1978). (Pubitemid 8302305)
51. Elder KA, Wolfe BM. Bariatric Surgery: A review of procedures and outcomes. Gastroenterology 132, 2253-2271 (2007). (Pubitemid 46693754)
52. Mun EC, Blackburn GL, Mathews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 120, 669-681 (2001). (Pubitemid 32171639)
53. Prachand VN, Ward M, Alverdy JC. Duodenal switch provides superior resolution of metabolic comorbidities independent of weight loss in the super- obese (BMI or= 50 kg/m2) compared with gastric bypass. J. Gastrointest. Surg. 14, 211-220 (2010).
54. Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super obese (BMI or=50kg/m2) compared with gastric bypass. Ann. Surg. 244, 611-619 (2006).
55. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am. J. Gastroenterol. 87, 775-779 (1992).
56. Friis R, Vaziri ND, Akbarpour F et al. Effect of rapid weight loss with supplemented fasting on liver tests. J. Clin. Gastroenterol. 9(2), 204-207 (1987). (Pubitemid 17046368)
57. Andersen T, Gluud C, Franzmann MB et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol. 12(2), 224-229 (1991).
58. Dixon JB, Bhathal PS, O'Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes. Surg. 16(10), 1278-1286 (2006). (Pubitemid 44671797)
59. Furuya CK Jr, de Oliveira CP, de Mello ES et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: Preliminary findings after 2 years. J. Gastroenterol. Hepatol. 22(4), 510-514 (2007). (Pubitemid 46434992)
60. Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137, 532-540 (2009).
61. Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann. Surg. 251(6), 1041-1048 (2010).
62. Moschen AR, Molnar C, Wolf AM et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J. Hepatol. 51(4), 765-777 (2009).
63. Cobb WS, Heniford BT, Burns JM et al. Cirrhosis is not a contra-indication to laparoscopic surgery. Surg. Endosc. 19, 418-423 (2005). (Pubitemid 40897946)
64. Takata MC, Campos GM, Ciovica R et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg. Obes. Relat. Dis. 4, 159-165 (2008).
65. Dallal RM, Mattar SG, Lord JL et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes. Surg. 14, 47-53 (2004). (Pubitemid 38130715)
66. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin. Gastroenterol. Hepatol. 9(10), 897-901 (2011).
67. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 39(6), 1647-1654 (2004). (Pubitemid 38702666)
68. Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 135(1), 48-58 (2004). (Pubitemid 38041453)
69. Clark JM, Alkhuraishi AR, Solga SF et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes. Res. 13(7), 1180-1186 (2005).
70. Mattar SG, Velcu LM, Rabinovitz M et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann. Surg. 242(4), 610-617 (2005).
71. Barker KB, Palekar NA, Bowers SP et al. Non-alcoholic steatohepatitis: Effect of Roux-en-Y gastric bypass surgery. Am. J. Gastroenterol. 101(2), 368-373 (2006). (Pubitemid 43381682)
72. Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes. Surg. 16(5), 607-611 (2006). (Pubitemid 43781046)
73. de Almeida SR, Rocha PR, Sanches MD et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes. Surg. 16(3), 270-278 (2006).
74. Klein S, Mittendorfer B, Eagon JC et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology 130(6), 1564-1572 (2006). (Pubitemid 43668832)
75. Mathurin P, Gonzalez F, Kerdraon O et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130(6), 1617-1624 (2006). (Pubitemid 43668847)